Join AbbVie scientists Shitalben Patel and Jami R. Erickson as they showcase their innovative advancements, transforming CETSA® into a high-throughput flow-based platform and introducing new whole blood formats to elevate drug discovery.

In this webinar, you’ll learn about flow-based CETSA, a powerful, high-throughput technique that enables single-cell target engagement analysis without cell lysis. Designed for screening of large compound libraries, this method overcomes traditional limitations like low throughput and high cell input. You will also hear how the method is being integrated into real-world SAR funnels to accelerate hit generation.

In the second half of the webinar, you will learn about novel Alpha and MSD CETSA formats for whole blood, using RIPK1 as a proof-of-concept. These assays require <100 μL of blood, eliminate PBMC isolation, and deliver clinically relevant, reproducible readouts—bringing true target engagement measurement closer to patient-derived samples.

Don’t miss this opportunity to explore how these CETSA innovations can transform your approach to drug discovery—from high-throughput screening to clinical translation.

All intellectual property rights, including copyrights and trademarks, relating to CETSA are owned by Pelago Bioscience AB.

Key Topics Include:

  • High-Throughput CETSA Innovation: Learn about the flow-based adaptation of CETSA, enabling rapid, large-scale compound screening using 384-well plates.
  • Flow Cytometry-Based Methodology: Discover how this technique detects thermostabilized proteins without cell lysis, allowing detailed single-cell analysis.
  • Application in Drug Discovery: See how flow-based CETSA integrates into SAR funnels, accelerating hit generation for endogenous targets in native cells.
  • Whole Blood CETSA Development: Explore two novel formats—Alpha CETSA and MSD CETSA—that use <100 μL blood and eliminate PBMC isolation.
  • Clinical Relevance: These blood-based assays enable direct, scalable target engagement readouts and support asynchronous, centralized clinical workflows
  • Translational Potential: Together, these innovations bridge preclinical research and clinical application, streamlining drug development in native biological systems.

Presenters

Shitalben Patel, ;MSc

Shitalben Patel, MSc

Scientist
Chemical Biology and Mass Spectrometry Technology, Discovery Research
AbbVie

Shitalben Patel is a Scientist in the chemical biology group at AbbVie. Her role involves developing high-throughput chemoproteomics workflows, employing chemical biology technologies to understand drug-target engagement, on and off-target selectivity profiling, as well as mechanism-of-action for small molecule drug discovery.
Jami R. Erickson, ;PhD

Jami R. Erickson, PhD

Senior Scientist
Molecular Screening and Characterization, Discovery Research
AbbVie

Dr. Jami R. Erickson is a Senior Scientist in the molecular screening and characterization group at AbbVie in North Chicago. Her work focuses on high-throughput screening and innovative technique development, including the pioneering of flow-based CETSA techniques.
Watch Webinar

Production Partner

Pelago Bioscience

At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® technology. Since then Pelago has become the leading CRO delivering actionable insights bridging the gap between pre-clinical studies and patient outcomes.

VIEW PROFILE
Pelago Bioscience

Additional Content From Scientist.com

Related Content